Endoscopic Retrograde Cholangiopancreatography Market: as Boston Scientific's EXALT-D single-use duodenoscope FDA clearance in December 2019 and commercial expansion convert the duodenoscope from a capital equipment purchase amortised over hundreds of procedures into a USD 700 to USD 1,000 per-procedure consumable that structurally doubles per-procedure revenue for the manufacturer versus the reusable model, so GLOBOCAN 2022's 511,000 annual pancreatic cancer cases generating biliary obstruction in approximately 60 to 70% of unresectable patients create a durable recurring metal biliary stent replacement demand at USD 400 to USD 1,200 per stent replaced every 3 to 6 months, and so the Boston Scientific AXIOS Japan regulatory approval for gallbladder drainage in 2024 and the 1.5 million annual global ERCP procedures together establish ERCP as one of the highest per-procedure consumable revenue endoscopy procedures in the global device market.

The global endoscopic retrograde cholangiopancreatography market size was USD 2.14 Billion in 2025 and is expected to register a revenue CAGR of 7.8% during the forecast period. Market revenue growth is driven by factors such as the infection-control mandate-driven transition from reusable to single-use duodenoscopes creating a new per-procedure premium revenue stream, the pancreatic and biliary cancer burden documented by GLOBOCAN 2022 at 511,000 new pancreatic cancer cases generating sustained biliary metal stent demand, as well as the Boston Scientific AXIOS Japan regulatory approval for gallbladder drainage in 2024 expanding the therapeutic ERCP accessory market into high-value gallbladder drainage applications. The first driving factor is the EXALT-D single-use duodenoscope commercial expansion. Boston Scientific Corporation reported Endoscopy division net sales of USD 2.687 Billion for fiscal year ended December 31, 2024, representing 8.3% reported and 8.0% organic growth year-on-year per the company's FY2024 Annual Report and 10-K filed with the US Securities and Exchange Commission, with double-digit growth specifically noted in single-use imaging platforms as a key driver. Boston Scientific stated in its EXALT-D FDA approval announcement that more than 1.5 million ERCPs are performed worldwide annually, establishing the procedure volume that generates per-procedure consumable demand for sphincterotomes, guidewires, biliary stents, and balloon extraction catheters. Olympus Corporation reported Endoscopic Solutions Business revenue of JPY 636,144 Million for FY2025 at 8.4% year-on-year growth per consolidated results, with reusable duodenoscopes, ERCP accessories, and endoscopy processors constituting the installed base generating recurring ERCP consumable demand. The second driving factor is the pancreatic cancer biliary obstruction stenting burden. GLOBOCAN 2022 documented 511,000 new pancreatic cancer cases with 467,000 deaths globally in 2022, with endoscopic biliary decompression via ERCP being the primary palliative intervention for obstructive jaundice in unresectable pancreatic cancer. The third driving factor is the Boston Scientific AXIOS stent Japan regulatory approval in 2024 for gallbladder drainage, expanding the therapeutic ERCP accessory market into a new high-value application at USD 1,800 to USD 2,500 per AXIOS stent. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each ERCP procedure regardless of indication requires a basket of per-procedure disposable accessories that generate predictable recurring revenue per case, encompassing guidewires at USD 30 to USD 80 per unit, sphincterotomes at USD 50 to USD 150 per unit, biliary extraction balloon catheters at USD 80 to USD 200 per unit, and biliary stents at USD 30 to USD 80 for plastic stents and USD 400 to USD 1,200 for self-expanding metal stents, creating a total per-ERCP-case accessory spend of USD 200 to USD 400 for a biliary stone extraction case and USD 400 to USD 1,200 for a malignant biliary obstruction stenting case in US hospital outpatient settings. Malignant biliary obstruction stenting generates recurring per-patient annual stent replacement revenue of USD 800 to USD 2,400 at replacement intervals of 3 to 6 months through the natural history of the cancer, because bile duct metal stents occlude with tumour ingrowth or biofilm and require replacement for continued biliary decompression. The Centers for Medicare and Medicaid Services reimburses ERCP procedures under Ambulatory Payment Classifications in the Hospital Outpatient Prospective Payment System, with CPT code 43264 for ERCP with endoscopic biliary stone removal reimbursed at approximately USD 1,180 in 2024 and CPT code 43267 for biliary stent placement at approximately USD 1,320. The ERCP procedure volume in Japan at approximately 200,000 procedures annually, and Brazil with approximately 80,000 annual ERCPs per the Brazilian Society of Digestive Endoscopy, establish the multi-country volume base generating per-procedure accessory demand. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the infection-control imperative driving the shift from reusable duodenoscopes to the EXALT-D single-use platform at US hospitals with documented contamination history or zero-tolerance infection control policies, creating a structural per-procedure revenue uplift that transforms the duodenoscope from a capital equipment item amortised over hundreds of procedures into a high-value per-procedure consumable. The FDA issued a Safety Communication in 2015 advising healthcare facilities of the infection risk from contaminated duodenoscopes and followed with a 2019 recommendation that high-volume ERCP facilities consider transitioning to duodenoscopes with disposable endcaps or fully single-use duodenoscopes to eliminate residual infection risk from inadequate reprocessing of the complex elevator mechanism within the distal tip. The EXALT Model D Single-Use Duodenoscope from Boston Scientific received FDA 510(k) clearance in December 2019 after FDA Breakthrough Device Designation, with a limited US market release in Q1 2020 followed by broader commercial expansion. Boston Scientific's Endoscopy division reported FY2024 net sales of USD 2.687 Billion growing 8.0% organically, with double-digit growth in single-use imaging platforms as a key ERCP driver, confirming the commercial momentum of the single-use transition. Each EXALT-D procedure generates approximately USD 700 to USD 1,000 in revenue from the single-use scope alone compared to approximately USD 70 to USD 250 per procedure amortisation from a reusable scope at USD 35,000 to USD 50,000 capital cost amortised over 200 to 500 procedures, representing a structural 3 to 10-fold per-procedure revenue uplift. The documented contamination incidents at Cedars-Sinai Medical Center, Ronald Reagan UCLA Medical Center, and Virginia Mason Medical Center between 2012 and 2018 generated sustained hospital administrator and physician awareness of reprocessing infection risk that sustains the infection-control imperative for single-use adoption at infection-sensitive US hospitals. The effect on the market is a structural duodenoscope revenue expansion as each hospital transitioning to EXALT-D converts a capital purchase cycle into a per-procedure consumable revenue stream that grows directly with ERCP procedure volume at that facility. These are some of the key factors driving revenue growth of the market.

The second driver is the pancreatic and biliary cancer burden generating a structurally durable recurring metal biliary stent demand that grows with cancer incidence and is one of the most reimbursement-insensitive ERCP device categories because the clinical necessity of biliary decompression for obstructive jaundice management in unresectable pancreatic cancer patients overrides procurement cost sensitivity at the individual patient level. GLOBOCAN 2022 documented 511,000 new pancreatic cancer cases and 467,000 deaths globally in 2022, with pancreatic cancer representing approximately 5% of all cancer deaths worldwide. Biliary obstruction from pancreatic head adenocarcinoma requires endoscopic biliary stenting via ERCP in the majority of patients with unresectable disease, with bile duct metal stents at USD 400 to USD 1,200 per unit replacing plastic stents at USD 30 to USD 80 as the standard palliation tool at high-volume ERCP centres because metal stents maintain biliary patency for 6 to 12 months versus 3 months for plastic stents, reducing the total ERCP procedure frequency per patient. ESMO 2024 guidelines and ESGE 2023 guidelines confirm ERCP with biliary metal stent insertion as the recommended first-line palliative procedure for malignant biliary obstruction in unresectable pancreatic cancer, establishing the clinical guideline mandate that sustains metal stent ERCP device demand regardless of reimbursement tariff environments. Boston Scientific's WallFlex Biliary RX Fully Covered Stent and WallFlex Biliary Uncovered Stent represent the commercial metal biliary stent portfolio generating sustained repeat replacement demand at 3 to 6 month intervals. Europe accounts for approximately 100,000 of the 511,000 annual global pancreatic cancer cases, with approximately 40,000 to 55,000 annual metal stent insertions just for pancreatic cancer palliation plus replacement stents. The effect on the market is a structural recurring ERCP accessories revenue base that grows with pancreatic cancer incidence and is substantially insensitive to healthcare system cost containment measures. These are some of the key factors driving revenue growth of the market.

Boston Scientific stated in its EXALT-D FDA approval announcement that more than 1.5 million ERCPs are performed worldwide annually using duodenoscopes to diagnose and treat pancreatic and biliary conditions, establishing the global annual procedure volume that generates per-procedure consumable demand. Boston Scientific Endoscopy division reported FY2024 net sales of USD 2.687 Billion at 8.0% organic growth, with double-digit growth in single-use imaging platforms and the AXIOS stent receiving Japan regulatory approval for gallbladder drainage in 2024 confirming continued ERCP accessory market expansion.

The third driver is the combined commercial expansion of ERCP procedure settings from hospital inpatient to ambulatory outpatient and freestanding surgery centre environments, simultaneously with the clinical application expansion from traditional biliary decompression into therapeutic gallbladder drainage using AXIOS lumen-apposing metal stents at premium per-procedure device pricing. ERCP procedures are progressively migrating from hospital inpatient to outpatient settings as anaesthesia capabilities at ambulatory centres have expanded to support moderate sedation and monitored anaesthesia care required for ERCP. CMS reimburses ERCP under Ambulatory Payment Classifications, with CPT code 43264 for biliary stone extraction reimbursed at approximately USD 1,180 in 2024 and CPT 43267 for biliary stent placement at approximately USD 1,320, supporting ERCP migration to ambulatory surgery centres. Boston Scientific received Japan regulatory approval for the AXIOS stent for gallbladder drainage in 2024, establishing EUS-guided cholecystoduodenostomy as a Japan-reimbursed endoscopic alternative to percutaneous cholecystostomy in high-surgical-risk patients with acute cholecystitis, with the AXIOS stent priced at approximately USD 1,800 to USD 2,500 per unit. FUJIFILM India's February 2024 ALOKA ARIETTA 850 installation at Fortis Hospital Bengaluru supporting EUS-ERCP combination procedures illustrates the expansion of ERCP-supporting ultrasound processor installations in Asian emerging markets. Japan's approximately 200,000 annual ERCP procedure volume, supported by national health insurance coverage and Japan Biliopancreatic Endoscopy Society infrastructure, sustains device procurement at Japanese hospital endoscopy programmes. The effect on the market is a revenue expansion from both new ASC ERCP procedure room equipment procurement and incremental AXIOS stent premium accessory revenue per gallbladder drainage case that adds to traditional biliary decompression accessory revenue. These are some of the key factors driving revenue growth of the market.

However, the ERCP market faces adoption constraints from the challenging economics of the single-use duodenoscope transition at cost-sensitive institutions, the post-ERCP pancreatitis complication rate, and advanced endoscopist shortages in lower-income markets. The EXALT-D at USD 700 to USD 1,000 per unit versus USD 70 to USD 250 amortised reusable cost per procedure creates a per-procedure cost premium that is commercially viable only at infection-control priority US hospitals or high-risk patient populations, while European public hospital procurement committees constrained by German DRG, French GHS, and UK NHS tariff frameworks find the EUR 600 to EUR 900 per scope single-use cost unsustainable versus EUR 50 to EUR 150 amortised reusable cost within episode-based reimbursement frameworks. The post-ERCP pancreatitis complication rate of approximately 3 to 5% in unselected patient populations and up to 15 to 20% in high-risk individuals limits the expansion of ERCP indications beyond clearly necessary biliary and pancreatic interventions into prophylactic applications. The shortage of trained advanced endoscopists in Latin America, sub-Saharan Africa, and South and Southeast Asia limits geographic expansion of ERCP procedure capacity beyond major urban academic medical centres. These factors substantially limit endoscopic retrograde cholangiopancreatography market growth over the forecast period.

Based on product, the global ERCP market is segmented into duodenoscopes, biliary and pancreatic stents, sphincterotomes, guidewires and cannulas, and stone extraction devices. Duodenoscopes hold the largest revenue share at approximately 38% of 2025 market revenue. Reusable duodenoscopes from Olympus (TJF-Q190V) and Pentax Medical (ED-34-i10T) are priced at USD 35,000 to USD 50,000 per instrument, generating recurring demand for reprocessing services, repair, and replacement every three to seven years. The single-use duodenoscope segment led by Boston Scientific EXALT Model D is expected to register the fastest revenue growth rate over the forecast period, driven by infection-control mandates, the per-procedure revenue premium over reusable platforms, and the elimination of reprocessing cost and risk. Biliary and pancreatic stents represent the highest-margin per-procedure consumable category, with self-expanding metal biliary stents at USD 400 to USD 1,200 per stent versus USD 30 to USD 80 for plastic stents, and malignant biliary obstruction generating recurring per-patient replacement stent demand every 3 to 6 months.

Based on technology, the global ERCP market is segmented into reusable systems, single-use disposable systems, and hybrid disposable-tip systems. Single-use systems are expected to register the fastest revenue growth rate over the forecast period, driven by the EXALT-D Breakthrough Device Designation and FDA 510(k) clearance in December 2019 that established the single-use duodenoscope concept, and by infection-control regulatory pressure converting a capital equipment purchase into a per-procedure consumable at a 3 to 10-fold per-procedure revenue uplift. The hybrid disposable-tip category, represented by Olympus's disposable distal cap system for its TJF-Q190V, provides a middle path between full single-use and conventional reusable configurations at lower per-procedure cost than full EXALT-D transition, serving European public hospital procurement committees managing episode-based tariff constraints.

Based on procedure, the global ERCP market is segmented into biliary sphincterotomy, biliary stenting, pancreatic duct stenting, and stone extraction. Biliary stenting holds the highest revenue per procedure because malignant biliary obstruction from pancreatic cancer, cholangiocarcinoma, and ampullary cancer requires self-expanding metal biliary stents at USD 400 to USD 1,200 per stent that are replaced every 3 to 6 months in patients with unresectable disease, generating recurring per-patient annual stent revenue of USD 800 to USD 2,400 from the growing pancreatic cancer patient base documented by GLOBOCAN 2022 at 511,000 new annual cases. The AXIOS stent Japan approval in 2024 for gallbladder drainage at USD 1,800 to USD 2,500 per unit represents the highest-value single-accessory application in the therapeutic ERCP market, with the premium pricing justified by the clinical benefit of eliminating percutaneous drainage surgery in high-risk patients.

Based on regional analysis, the ERCP market in North America accounted for the largest revenue share in 2025 at approximately 38% of global revenue. The United States drives the regional position through the highest per-procedure device pricing globally, the earliest and most widespread adoption of single-use duodenoscope platforms driven by FDA safety communications and high-profile infection outbreak litigation, and the largest advanced endoscopy trained physician workforce per capita outside Japan. CMS reimbursement under CPT codes 43260 through 43274 covers ERCP procedures in hospital inpatient and outpatient ambulatory surgery centre settings, supporting per-procedure device procurement across approximately 700,000 estimated annual US ERCP procedures. Boston Scientific's Endoscopy division with USD 2.687 Billion FY2024 net sales anchors the North American ERCP device position through EXALT-D single-use platform leadership and WallFlex biliary stent market share.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, Italy, and the Netherlands represent the five largest national ERCP device markets. ESGE's 2023 clinical practice guidelines updated ERCP as the recommended first-line procedure for biliary stone extraction, malignant biliary obstruction palliation, and biliary stricture evaluation. EU MDR Class IIb conformity requirements for endoscopy reprocessing systems and Class III for implantable biliary stents establish the European regulatory framework. European adoption of single-use EXALT-D remains constrained by EUR 600 to EUR 900 per scope cost versus EUR 50 to EUR 150 amortised reusable cost in public hospital procurement frameworks. Iran-US sanctions disruptions to Strait of Hormuz shipping corridors have maintained elevated polymer and fluoropolymer raw material costs affecting biliary stent and guidewire manufacturing supply chains serving European production facilities through 2026.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, India, and Australia represent the five largest national ERCP markets. Japan maintains the highest per-capita ERCP procedure volume outside the United States at approximately 200,000 annual ERCPs, with NHI coverage and Japan Biliopancreatic Endoscopy Society infrastructure sustaining device procurement. Boston Scientific received Japan regulatory approval for the AXIOS stent for gallbladder drainage in 2024, expanding the therapeutic ERCP accessory market. China's expanding tertiary hospital endoscopy infrastructure under Healthy China 2030 is generating new ERCP procedure volume at provincial and municipal hospitals, leaving more room for Asia Pacific market growth than in North America where ERCP device market penetration at tertiary hospital programmes is already higher.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil, Mexico, Colombia, and Argentina represent the four largest national ERCP markets. Brazil's public healthcare system covers ERCP at accredited endoscopy centres with approximately 80,000 annual ERCPs per the Brazilian Society of Digestive Endoscopy. The high prevalence of gallstone disease in Latin American populations supports a structurally elevated ERCP procedure volume for biliary stone extraction. The indirect effects of Iran-US conflict supply chain disruptions continue to affect specialty fluoropolymer and polymer component imports into Latin American ERCP device distributors through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, the UAE, Egypt, South Africa, and Turkey represent the primary national ERCP device markets. GCC healthcare infrastructure expansion under Vision 2030 has driven new tertiary hospital endoscopy suite installations generating new ERCP procedure room capacity. The Saudi Food and Drug Authority regulates endoscopy devices under the Medical Device Interim Regulation framework with Class C classification for active endoscopy systems. Olympus distributes duodenoscopes and accessories through established South African medical device distribution partnerships at Netcare and Life Healthcare private hospital endoscopy programmes.